Aprea Therapeutics raises $30M, confirms partial response for APR-1051 in Phase 1 trial

Aprea Therapeutics, Inc.

Raised ~$30M via pre-funded warrants ($0.808) and common warrants ($0.683) expiring Dec. 31, 2029; led by Soleus Capital.
Confirmed partial response in PPP2R1A-mutated endometrial cancer patient at 220 mg; target lesion reduction 59.5%, CA-125 drop from 362 to 40.2 U/mL.
Two partial responses in endometrial cancer with PPP2R1A mutations; five stable diseases including HPV+ HNSCC, colorectal, and endometrial cancers.
Cash runway extended into Q1 2028; dose escalation to 300 mg QD planned in Q2 2026.
Oversubscribed offering; Oppenheimer & Co. and Maxim Group acted as placement agents.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Gross proceeds of approximately $30 million (effective 2026-03-30).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: Gross proceeds of approximately $30 million
Effective: 2026-03-30

Exact text from the filing

On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to approximately 37.2 million shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.683 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-036821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.